ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,770.20
0.55%
US Tech 100
19,636.04
0.55%
다우존스 지수
42,801.72
0.52%
Bitcoin
84,501.57
-1.92%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. scPharmaceuticals Inc (SCPH)

  7. scPharmaceuticals Inc (SCPH) 뉴스

scPharmaceuticals Inc

scPharmaceuticals Inc (SCPH)

NASDAQ
2.93
-0.19
(-6.09%)
마감 09 3월 5:00AM
15분 지연
2.8801
-0.0499
(-1.70%)
시간외 거래: 9:56AM
15분 지연

개인 투자자를 위한 전문가급 도구.

프리미엄

SCPH 뉴스

공식 뉴스 전용

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
13 2월 2025
SCPH (-6.09%)

Form 8-K - Current report
Edgar (US Regulatory)
10 1월 2025
SCPH (-6.09%)

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
Edgar (US Regulatory)
31 12월 2024
SCPH (-6.09%)

Form 8-K - Current report
Edgar (US Regulatory)
11 12월 2024
SCPH (-6.09%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
14 11월 2024
SCPH (-6.09%)

Form 8-K - Current report
Edgar (US Regulatory)
14 11월 2024
SCPH (-6.09%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
15 8월 2024
SCPH (-6.09%)

Form 8-K - Current report
Edgar (US Regulatory)
15 8월 2024
SCPH (-6.09%)

Form 8-K - Current report
Edgar (US Regulatory)
13 8월 2024
SCPH (-6.09%)

SCPH Discussion

게시물 보기
FooBarAndGrill FooBarAndGrill 10 월 전
What a freaking dud. $SCPH
👍️0
FooBarAndGrill FooBarAndGrill 12 월 전
March 13, 2024 - 10K
2023 Product revenues, net $13,593,000
Net loss 2022 $36,838,000 /// 2023 $54,810,000
Net loss per share, basic and diluted 2022 $1.30 /// 2023 $1.42
https://www.sec.gov/ix?doc=/Archives/edgar/data/1604950/000095017024030780/scph-20231231.htm
👍️0
FooBarAndGrill FooBarAndGrill 1 년 전
FUROSCIX® Revenue

Company anticipates Q4 2023 net FUROSCIX revenue to be approximately $5.9 to $6.1 million; full-year net FUROSCIX revenue of approximately $13.4 to $13.6 million

Gross-to-net (GTN) discount of approximately 18% from launch through the end of Q4

Inventory levels at the end of Q4 2023 consistent with the end of Q3 2023

Unaudited cash, cash equivalents and short-term investments of approximately $76 million as of December 31, 2023
👍️0
FooBarAndGrill FooBarAndGrill 1 년 전
Ba-Donka-Donk
👍️0
FooBarAndGrill FooBarAndGrill 1 년 전
Third Quarter 2023 Financial Results and Financial Guidance

Product revenues were $3.8 million, and cost of product revenues were $1.1 million for the third quarter of 2023.

Research and development expenses were $3.4 million for the third quarter of 2023, compared to $3.7 million for the third quarter of 2022. The decrease in research and development expenses for the quarter ended September 30, 2023 was primarily due to a decrease in employee related costs and clinical study and medical affairs costs. The decrease was partially offset by an increase in device and pharmaceutical development costs.

Selling, general and administrative expenses were $14.1 million for the third quarter of 2023, compared to $6.3 million for the third quarter of 2022. The increase in selling, general and administrative expenses for the quarter ended September 30, 2023 was primarily due to an increase in employee related costs and commercial costs.

scPharmaceuticals reported a net loss of $15.6 million for the third quarter of 2023, compared to $10.2 million for the third quarter of 2022.

scPharmaceuticals ended the third quarter of 2023 with $90.2 million in cash, cash equivalents and short-term investments, compared to $118.4 million as of December 31, 2022.

As of September 30, 2023, scPharmaceuticals’ total shares outstanding was 35,859,045.

Full PR Here
👍️0
FooBarAndGrill FooBarAndGrill 2 년 전
$SCPH is literally asleep at the wheel. Did anyone attend the conference call?
👍️0
FooBarAndGrill FooBarAndGrill 2 년 전
Medicaid coverage of FUROSCIX effective July 1, 2023.
👍️0
FooBarAndGrill FooBarAndGrill 2 년 전
$SCPH Institutional Ownership 87.19%
https://www.nasdaq.com/market-activity/stocks/scph/institutional-holdings
👍️0
FooBarAndGrill FooBarAndGrill 2 년 전
In addition, we were also recently informed that we’ll obtain national Medicaid coverage of FUROSCIX effective July 1, 2023. https://seekingalpha.com/article/4602856-scpharmaceuticals-inc-scph-q1-2023-earnings-call-transcript
👍️0
FooBarAndGrill FooBarAndGrill 2 년 전
10-Q + Webcast Wed 4:30pm ET. This will include sales from go-to-market FEB 20 thru MAR 31.
https://scpharmaceuticalsinc.gcs-web.com/news-releases/news-release-details/scpharmaceuticals-announce-first-quarter-2023-financial-results
👍️0
FooBarAndGrill FooBarAndGrill 2 년 전
scPharmaceuticals Inc. discloses that it has two deposit accounts at Silicon Valley Bank, each with a balance of equal to or less than $250,000 as of March 10, 2023.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1604950/000119312523067253/d483112d8k.htm
👍️0
FooBarAndGrill FooBarAndGrill 2 년 전
$SCPH PR:
https://www.globenewswire.com/news-release/2023/02/21/2612086/0/en/scPharmaceuticals-Announces-Launch-and-Commercial-Availability-of-FUROSCIX-furosemide-injection.html
👍️0
FooBarAndGrill FooBarAndGrill 2 년 전
Monday 20th is Go-To-Market.
👍️0
FooBarAndGrill FooBarAndGrill 2 년 전
SCPH provides business updates.
https://www.globenewswire.com/news-release/2023/01/30/2597485/0/en/scPharmaceuticals-Provides-FUROSCIX-furosemide-injection-Commercial-Update.html
👍️0
FooBarAndGrill FooBarAndGrill 2 년 전
Will $SCPH ever sell a single dose of this FDA approved drug? This is the Twilight Zone.
👍️0
FooBarAndGrill FooBarAndGrill 2 년 전
The go-to-market for the Furoscix infusor/drug combo is a large undertaking. It involves building out production for both the infusor and drug. Quality control is the name of the game.
👍️0
FooBarAndGrill FooBarAndGrill 2 년 전
Furoscix administered via the Furoscix Infusor.

In addition to the Ph-Neutral formulation of Furoscix, FDA has approved the use of an automatic infusor for administration of the prescribed dosage.

Furoscix enables subcutaneous administration at home by the patient or a caregiver with the use of the On-Body Infusor, which was developed using West Pharmaceutical Services SmartDose technology. Once the pre-filled cartridge is inserted into the pre-programmed infusor and attached to the abdomen, the device is activated to deliver the 80-mg dose over five hours.

https://clinicaltrials.gov/ct2/show/NCT03458325
https://www.empr.com/home/news/fda-approves-wearable-furosemide-delivery-system-furoscix-for-outpatient-use/
👍️0
FooBarAndGrill FooBarAndGrill 2 년 전
$SCPH Prescription Drug product FUROSCIX has been added to United Healthcare's Pharmacy Benefit Programs Drug List.
https://www.uhcprovider.com/content/dam/provider/docs/public/resources/pharmacy/Drugs-with-Clinical-Programs-Commercial.pdf
👍️0
FooBarAndGrill FooBarAndGrill 2 년 전
$SCPH Prescription Drug product FUROSCIX has been added to Humana's List of covered drugs.
https://docushare-web.apps.external.pioneer.humana.com/Marketing/docushare-app?file=4473924
👍️0
FooBarAndGrill FooBarAndGrill 2 년 전
PDUFA! Approval!
https://scpharmaceuticalsinc.gcs-web.com/news-releases/news-release-details/scpharmaceuticals-announces-fda-approval-furoscixr-furosemide
👍️0
FooBarAndGrill FooBarAndGrill 2 년 전
PDUFA! Approval!
https://scpharmaceuticalsinc.gcs-web.com/news-releases/news-release-details/scpharmaceuticals-announces-fda-approval-furoscixr-furosemide
👍️0
FooBarAndGrill FooBarAndGrill 2 년 전
PDUFA After Market today?
👍️0
akamaii akamaii 6 년 전
What’s up here today
👍️0

최근 히스토리

NASDAQ
SCPH
scPharmaceuticals
BIT
ENEL
Enel
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지